Startups
MindRank (www.mindrank.ai) is an AI-driven biotech company with focus on “Undruggable” targets. The company started operations in 2021 and now consists of 35 scientists with R&D center in China and UK. The company is led by academicians of the British Royal Society, former R&D scientists from top pharma companies and the global AI competition winners. The team has successful experience in drug R&D and have a large number top publications including Nature Biomedical Engineering, Nature Machine Intelligence, Patterns (Cell Press) etc. By leveraging its proprietary AI driven drug discovery platform, MindRank has delivered a small molecule Preclinical Candidate (allosteric inhibitor) to a listed biotechnology company in Sept 2021. In Jan 2022, MindRank begins IND-enabling studies of its proprietary AI-designed drug (Class B GPCR), 8 months after program initiation. Both of the small molecule drugs are expected to enter clinical phase in 2022.
Overview
Location
China
Employees
11-50
Total raised
$52M
Founded date
2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 12, 2026 | MindRank Raises $52 Million In Series B Financing To Advance AI-Native Drug Development | MindRank AI, a clinical-stage biotechnology company developing an artificial intelligence-powered drug research and development platform, announced that it has raised $52 million in Series B financing. The funding round was led by a group o... |
| Jun 14, 2023 | MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China | SHANGHAI and HANGZHOU, China, June 14, 2023 /PRNewswire/ -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced today that the first healthy volunteer dosed in the Phase 1 study of their oral ... |
| Dec 26, 2022 | MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity | SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ -- MindRank, an artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigation... |
| Dec 26, 2022 | MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity | SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ -- MindRank, an artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigation... |
| MindRank AI | “One-stop, AI-powered small molecule drug discovery platform.” |
Reviews 0
FAQ about MindRank AI
When was MindRank AI founded?
MindRank AI was founded in 2021.
How much funding has MindRank AI raised?
MindRank AI has raised $52M in total across 1 funding round.
What has the press written about MindRank AI?
Parsers VC has collected 6 articles mentioning MindRank AI, among them “MindRank Raises $52 Million In Series B Financing To Advance AI-Native Drug Development” (Jul 12, 2026) and “MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China” (Jun 14, 2023).
Is MindRank AI still active?
MindRank AI is probably closed: its latest activity on Parsers VC dates from Jul 14, 2026.